Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
NCT02311569
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Myeloproliferative Neoplasm
Primary Myelofibrosis
Essential Thrombocythemia
Polycythemia Vera
Interventions
DRUG:
Mirabegron
Sponsor
Swiss Cancer Institute